CORE Biomedicine licenses global rights to Eisai preclinical oncology programs

The deal gives CORE exclusive worldwide development and commercialization rights to multiple cancer drug candidates as it builds a precision medicine pipeline across the United States, Japan and China.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.